knowledge -WSS

knowledge

author：entertainment 2025-09-29 19:05:55 - browse：715

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

The benefits and risks of Eli Lilly’s treatment for Alzheimer’s disease were confirmed in detailed scientific disclosures Monday, paving the way for its full approval but leaving physicians with lingering questions about the medicine’s impact on patients as a new era in Alzheimer’s therapy unfolds.

The drug, called donanemab, showed a 35% slowing of Alzheimer’s disease progression relative to placebo in a clinical trial that enrolled 1,700 patients with early-stage disease. Numerically, that’s a modest, 3.3-point improvement on a 144-point survey, called the Integrated Alzheimer’s Disease Rating Scale, or iADRS, that combines measures of cognition and function, such as driving, managing finances, or carrying on conversations.

There was a similar benefit when donanemab’s efficacy was assessed using a more common measure of cognition called the Clinical Dementia Rating-Sum of Boxes, or CDR-SB. On that scale, the Lilly drug showed a 36% slowing of cognitive decline relative to placebo, or 0.68 points on an 18-point scale.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Physician executives need more than on

WSS

Biogen’s boardroom scandal saddles CEO with first crisis

FDA rejects Alnylam's heart disease treatment over insufficient data

Sweeping indictment could be Trump's biggest legal challenge yet: ANALYSIS

VC firm General Catalyst wants to buy a health system

Liquid biopsy for lung cancer is launched by Delfi

Aspartame and sugar

knowledge

knowledge

hotspot

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

The future of health care in the House

Wildfire smoke exposes gaps in outdoor worker protections

FDA panel signals lack of confidence in Amgen cancer drug data

Psychedelics group wrestles with new pharma identity

Readout Newsletter: Biotech news, including Moderna's Covid vaccine

Virginia high school admissions case could be legal follow

What to know about the judge who will handle the Trump case

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Dozens dead from Maui wildfires: What we know about the victims

hotspot

FDA panel signals lack of confidence in Amgen cancer drug data

Megan Rapinoe shares emotional post following US Women's World Cup exit

Senate panel eyes new effort on drug shortages

Why Charlie Gard's case is so disturbing to Americans

Schizophrenia gene found to be linked to cells' energy dysfunction

Idaho college killings prosecutors challenge defense's grand jury claims

focus

hotspot

focus

knowledge